The role of vitamins in stroke prevention has been studied
|
|
- Godwin Hubbard
- 5 years ago
- Views:
Transcription
1 Emerging Therapy Critiques The Role of Vitamin B in Stroke Prevention A Journey From Observational Studies to Clinical Trials and Critique of the VITAmins TO Prevent Stroke (VITATOPS) Gustavo Saposnik, MD, MSc, FAHA All truths are easy to understand once they are discovered; the point is to discover them. Galileo Galilei (1564 to 1642), Italian physicist, astronomer, and philosopher The role of vitamins in stroke prevention has been studied for decades. Folate and cyanocobalamin (vitamin B12) are important regulators of the metabolism of homocysteine. Studies have shown that low levels of these factors are associated with elevation of homocysteine in the blood. 1,2 Hyperhomocysteinemia has been associated with premature atherosclerosis with an increased risk of cardiovascular events. 3 5 On the basis of epidemiological studies, clinicians and scientists expected that homocysteine-lowering therapy (HLT) with appropriate doses of folic acid, Vitamin B6, and Vitamin B12 supplementation would reduce the incident risk of cardiovascular diseases (including stroke). As a result, HLT has been tested in several double-blind, randomized controlled trials (Table 1) I discuss the results of the recently published VITAmins TO Prevent Stroke (VITATOPS) trial in the context of the current available evidence. 15 Needless to say, this article is not a comprehensive review, but rather it intends to highlight some of the current and relevant aspects of Vitamin B supplementation for stroke prevention. As such, several questions will remain to be answered. The VITATOPS Trial VITATOPS was a double-blind, placebo-controlled trial, in which 8164 patients with a recent stroke or transient ischemic attack were randomized to receive placebo or 2 mg folic acid, 25 mg Vitamin B6, and 0.5 mg Vitamin B12 in a single tablet. 15 Follow-up ranged to nearly 12 years with a median of 3.5 years. The qualifying events were ischemic (88%), hemorrhagic (10%), and unknown (2%). Of the ischemic events, large artery disease was the most common stroke mechanism, and approximately one third of patients had small vessel disease. Patients were ethnically diverse: 42% white, 24% Asian, 26% southern Asian, and 7% other. The primary outcome was nonfatal stroke, nonfatal myocardial infarction, or vascular death. Among participants, 616 (15%) patients assigned to B vitamins and 678 (17%) assigned to placebo reached the primary end point (risk ratio [RR] 0.91; 95% CI, 0.82 to 1.00; P 0.05; absolute risk reduction, 1.56%; 0.01 to 3.16). No significant benefit was observed for stroke reduction (RR, 0.92; 0.81 to 1.06). There were no serious adverse reactions and no significant differences in common adverse effects between the treatment groups. Neither adherence to medication nor follow-up was different between groups. Complete follow-up was available in 91% of patients. 15 The Good and the Bad VITATOPS was an investigator-driven trial over a period of 12 years. 15 The investigators are to be commended for their efforts in conducting this large trial over 12 years but, importantly, for obtaining funding to study an inexpensive product (B vitamins), which is commercially available and would be unlikely to generate a substantial revenue per pill for any sponsor. Unfortunately, the results of the VITATOPS do not provide sufficient evidence to support B vitamin supplementation for secondary stroke prevention. Rather, it adds more controversy to the current debate. What Do We Not Know? As mentioned, Vitamin B therapy has been associated with homocysteine reduction, also called HLT. Epidemiological studies and clinical trials showed that a 20% to 25% relative reduction in homocysteine levels (which correlated with 2.5 to 3 mol/l absolute reduction) is associated with a significant reduction in cardiovascular events. Further reductions are less likely to be effective. 16 Data from the reanalysis of the Vitamin Intervention for Stroke Prevention (VISP) and Heart Outcomes Prevention Evaluation (HOPE) 2 studies showed a graded effect in homocysteine reduction and clinical outcomes Unfortunately, homocysteine levels in Received December 15, 2010; accepted December 30, From the Stroke Outcomes Research Unit, Stroke Outcomes Research Canada (SORCan), Division of Neurology, Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada; the Institute for Clinical Evaluative Sciences & Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada; and the Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Correspondence to Gustavo Saposnik, MD, MSc, FAHA, 55 Queen Street East, Suite 931, St Michael s Hospital, University of Toronto, Toronto, M5C 1R6, Canada. saposnikg@smh.ca (Stroke. 2011;42:00-00.) 2011 American Heart Association, Inc. Stroke is available at DOI: /STROKEAHA
2 2 Stroke March 2011 Table 1. Baseline Characteristics of Participants in Double-Blind, Randomized Controlled Trials of Vitamin Therapy Design Daily Dose, mg Outcome Measures Trial No. Randomized Countries Mean Age, Years Target Population Duration of Treatment Folic Acid Vitamin B12 Primary End Point Effect on Primary Outcome RR (95% CI) Effect on Stroke RR (95% CI) ASFAST Australia, New Zealand 57 KD Composite 0.98 ( ) 0.60 ( )* VISP US, Canada, UK 66 Stroke / /0.02 Recurrent stroke 1.0 ( )... NORVIT Norway 63 CHD Composite 1.08 ( ) 1.02 ( ) SEARCH UK 64 CHD Composite 1.04 ( ) 1.02 ( ) HOPE US, Canada, Western Europe, Brazil, and Slovakia 69 CVD Composite 0.95 ( ( ) LNIS US 54 (median) Esophageal dysplasia Death (cerebrovascular) 0.67 ( )... HOST US 65 KD Death 1.04 ( ) 0.90 ( ) WENBIT Norway 61 CHD Composite 1.09 ( ) 0.87 ( ) WAFACS US 63 CVD Composite 1.03 ( ) 1.14 ( ) VITATOPS countries 63 CVD Composite 0.91 ( ) 0.92 ( ) *Estimated relative risk. Reported risk ratio in other publications 0.45 ( ). KD indicates kidney disease (chronic/end-stage renal disease), CHD, coronary heart disease; CVD, cardiovascular disease; Composite, stroke, CHD events, or death; VISP, Vitamin Intervention for Stroke Prevention; HOST, Homocystinemia in Kidney and End Stage Renal Disease; HOPE 2, Heart Outcomes Prevention Evaluation 2; NORVIT, Norwegian Vitamin Trial; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; WAFACS, Women s Antioxidant and Folic Acid Cardiovascular Study; WENBIT, Western Norway B Vitamin Intervention Trial; ASFAST, Atherosclerosis and Folic Acid Supplementation Trial; LNIS, Linxian Nutrition Intervention Trial. VITATOPS were not available for most of patients as per financial limitations. 15 Therefore, the published results based on the effect of Vitamin B therapy in the overall studied population provide limited estimation of the real effect once the target homocysteine reduction is achieved. The marginal benefits in favor of Vitamin B therapy were also likely diluted by the use of lower doses of Vitamin B12 (0.5 mg). 15 Elderly individuals require higher doses of B12 such as 1000 g/day to achieve adequate absorption. 20 Spence has discussed the key role of metabolic B12 deficiency, the interpretation of clinical trials, and the differences between myocardial infarction and stroke. He emphasizes that strokes are much more likely to be embolic, but thrombosis is more important in stroke pathogenesis. Elevated homocysteine quadruples the risk of stroke in atrial fibrillation. 21 The role of homocysteine and HLT in different stroke subtypes (eg, cardioembolic, large artery atherosclerotic disease, etc) has not been established. Kidney Function: A Marker or Confounder? Some studies showed Vitamin B therapy may be harmful in patients with an underlying nephropathy. For example, in the DIVINe trial (Diabetic Intervention with Vitamins to Improve Nephropathy), 238 participants who had Type 1 or 2 diabetes and a clinical diagnosis of diabetic nephropathy were randomized to a single tablet of B vitamins containing folic acid (2.5 mg/day), Vitamin B6 (25 mg/day), and Vitamin B12 (1 mg/day) or matching placebo. 22 For the primary outcome, radionuclide glomerular filtration rate (primary outcome) decreased by a mean (SE) of 16.5 (1.7) ml/min/1.73 m 2 in the Vitamin B group compared with 10.7 (1.7) ml/min/ 1.73 m 2 in the placebo group (mean difference, 5.8; 95% CI, 10.6 to 1.1; P 0.02) at 36 months. There was a mean 2.2 mol/l reduction in the homocysteine level in the Vitamin B group and a mean 2.6 mol/l increase in the placebo group. 22 Perhaps more importantly, there was a doubling of cardiovascular events with Vitamin B therapy that was confined to the patients with glomerular filtration rate 50 ml/min/1.73 m In another randomized trial including 2056 participants with advanced chronic kidney disease (estimated creatinine clearance 30 ml/min; n 1305) or end-stage renal disease (n 751) and high homocysteine levels ( 15 mol/l), high doses of B vitamins (40 mg of folic acid, 100 mg Vitamin B6, and 2 mg Vitamin B12) showed no reduction in death, myocardial infarction, or stroke over placebo. 12 In VITATOPS, there was a significant reduction for the primary outcome among patients with normal creatinine levels ( 120 mmol/l; RR, 0.83; 95% CI, 0.72 to 0.96) but not for their counterparts (creatinine 120 mmol/l; RR, 0.89; 95% CI, 0.65 to 1.21). Data should be interpreted with caution as for the nonsignificant probability value for the interaction (P 0.80). 15 Together, these data merit some considerations: (1) Vitamin B therapy may be harmful in patients with impaired renal function; (2) the true effect of Vitamin B therapy in previous randomized trials, including cardiovascular outcomes, might have been diluted by the inclusion of patients with reduced glomerular filtration rate); and (3) in patients with renal failure and stroke, the more active forms of cyanocobalamin and folic acid (methylcobalamin and tetrahydrofolate) may help decrease the hyperhomocysteinemia. 24 What Have We Learned? In a recent meta-analysis including 13 randomized controlled trials that enrolled participants, the authors found a lower incident risk of stroke (RR, 0.83; 95% CI, 0.71 to 0.97; P 0.02) for the combination of folic acid with Vitamins B6 and B No significant benefit was found for the use of single folic acid supplementation compared with controls
3 Saposnik Vitamin B in Stroke Prevention 3 Table 2. Summary of Meta-Analysis Reporting Stroke Outcomes Total No. of Active Control Meta-Analysis No. of Trials Key Inclusion Criteria Outcome Participants (Active/Control) Events Event Rate, % Events Event Rate, % Risk Ratio (95% CI) Wang et al 16 8 RCT with folic acid supplementation Stroke was an end point Any Stroke (8949/7892) ( ) More than 10 events Hcy 20% (2325/2180) ( ) Hcy 20% (4967/4051) ( ) Lee et al RCT Folic acid supplementation with or Any Stroke (20 415/18 590) ( ) without Vitamin B6 or B12 Ischemic (8338/8362) ( ) Inactive or very low dose control Report of total participants and stroke events in active and control group Clarke et al 26 8 Double blind RCT Relevant treatment arms differed only Any Stroke (18 723/18 762) ( ) with respect to lower Hcy levels Ischemic (NR) ( ) At least 1000 participants Duration of the intervention 12 months Bazzano et al RCT Folic acid supplementation with or Any Stroke (7432/6374) ( ) Mei et al RCT Folic acid supplementation with or Any stroke (18 785/18 327) ( ) Miller et al RCT Folic acid supplementation with or Any Stroke (19 444/19 497) NR NR NR NR 0.95 ( ) RCT indicates randomized controlled trial; Hcy, homocysteine; NR, not reported. (RR, 0.93; 95% CI, 0.85 to 1.03). 25 Formal testing did not reveal any substantial resulting heterogeneity or publication bias. In another recent meta-analysis including 8 randomized trials (with at least 1000 participants and follow-up data for a minimum of 1 year and appropriate doses of folic acid) involving individuals during a median follow-up of 5 years, folic acid allocation had no significant effects on vascular outcomes with rate ratios (95% CIs) of 1.01 (0.97 to 1.05) for major vascular events, 1.03 (0.97 to 1.10) for major coronary events, and 0.96 (0.87 to 1.06) for stroke. Four of the included randomized controlled trials use no or low doses (0.4 mg) of Vitamin B Interestingly, the treatment reached the expected target because there was an overall 25% mean reduction in homocysteine levels in individuals in the vitamin group compared with those in the placebo group. Other meta-analysis showed similar results (Table 2). 16,25 29 With the exception of the HOPE 2 trial 10 and reanalysis of VISP, 17,18 the remaining randomized studies showed no significant benefit in the reduction of stroke. Only 2 trials (VISP and VITATOPS) primarily randomized patients with previous stroke or transient ischemic attacks. 15,17 Previous meta-analysis using similar inclusion criteria reported a nonsignificant reduction in cardiovascular disease (RR, 0.95; 95% CI, 0.88 to 1.03), coronary heart disease (RR, 1.04; 95% CI, 0.92 to 1.17), or stroke (RR, 0.86; 95% CI, 0.71 to 1.04) for folic acid supplementation (in some combined with Vitamin B). 27 Contrarily, other authors reported a significant 18% (RR, 0.82; 95% CI, 68 to 100) reduction in the risk of stroke by focusing on a subset (7 of the previous 12 randomized studies) and added a randomized trial from China 16,30 The benefit was greater in those trials with longer treatment duration ( 36 months; RR, 0.71, 95% CI, 0.57 to 0.87), blood level reduction of homocysteine of 20% (RR, 0.77; 95% CI, 0.63 to 0.94; Table 2), and no history of stroke (RR, 0.75; 95% CI, 0.62 to 0.90). 16 Critiques to some of these trials include the use of lower doses of multivitamins, short intervention, limited number of stroke patients/events, and lack of complete homocysteine measures. 31 How Many More Clinical Trials and Meta-Analyses Do We Need to Determine the Role of Vitamin B Therapy in Stroke Prevention? There are already several observational and randomized trials of HLT reporting on the risk of myocardial infarction and stroke. Interestingly, 4 meta-analyses reporting on the benefit of folic acid or Vitamin B supplementation were just published in 2010 (Table 2). 25,26,28,29 Concordant observational data from cohort studies with over 10 years prospective follow-up showed that a
4 4 Stroke March % lower homocysteine level (approximately 3 mol/l [0.41 mg/l]) was associated with an 11% (OR, 0.89; 95% CI, 0.83 to 0.96) lower ischemic heart disease and 19% (OR, 0.81; 95% CI, 0.69 to 0.95) lower stroke risk. 32 Some meta-analyses have confirmed this finding. 16 However, the overall results of randomized clinical trials (the recently reported Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine [SEARCH], 9 Western Norway B Vitamin Intervention Trial [WENBIT], 13 Women s Antioxidant and Folic Acid Cardiovascular Study [WAFACS], 14 SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids [SU.FOL.OM3], 33 VITATOPS, 15 and the previously reported Linxian Nutrition Intervention Trial [LNIS], 11 Atherosclerosis and Folic Acid Supplementation Trial [ASFAST], 6 Homocystinemia in Kidney and End Stage Renal Disease [HOST], 12 VISP, 7 Norwegian Vitamin Trial [NORVIT], 8 HOPE 2 10 ), and most recent meta-analyses of folic acid supplementation in vascular prevention (composite outcome) showed consistent negative results. The association of vitamin deficiency and higher incident risk of a medical condition in observational studies with lack of risk reduction in randomized clinical trials is not new in medicine. Similar findings were observed for in studies analyzing the antioxidants properties of Vitamin C, Vitamin E, and beta-carotene How About Stroke? Together the reanalysis of the VISP trial and HOPE 2 trials is more encouraging. 10,17 19 In HOPE 2, the benefit favoring HLT remained after adjusting for concomitant antithrombotics, lipid-lowering, and antihypertensive treatment at study entry (hazard ratio, 0.71; 95% CI, 0.56 to 0.91). 19 Because both hypercholesterolemia and hyperhomocysteinemia can synergistically accelerate atherosclerosis in individuals at risk, treating both conditions may be a more effective intervention in stroke prevention. On the basis of the results of subgroup analysis from meta-analysis, only selected patients (ie, those with no history of stroke living in areas with no grain fortification or those with elevated baseline homocysteine levels capable of responding to HLT) may benefit with the long-term supplementation of appropriate doses of multivitamins (2.5 mg folic acid, 50 mg Vitamin B6, and 1 mg Vitamin B12) for stroke prevention. 16 Another meta-analysis with more restricted criteria showed no benefit in stroke reduction even when there was an overall 25% mean reduction (target usually accepted as effective) in homocysteine levels. 26 At the present time, the general or routine use of folic acid supplementation for cardiovascular prevention is not beneficial. The recent published Guidelines for the Primary Prevention of Stroke 37 state that the use of the B-complex vitamins, pyridoxine (B6), cobalamin (B12), and folic acid might be considered for prevention of ischemic stroke in patients with hyperhomocysteinemia, but its effectiveness is not well established (Class IIb; Level of Evidence B). A similar level of recommendation is provided in the Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack (Secondary prevention). 38 Although possible, another trial powered to detect an absolute reduction in the risk of stroke with appropriate dose of vitamin supplements and long follow-up is unlikely to happen. The potential low-profit, likely marginal (if demonstrated) clinical effects of HLT and required efforts to conduct a large multicenter trial make this less attractive to sponsors. Several questions remain to be answered regarding the benefit of Vitamin B complex therapy (or HLT) before (and after!) the results of the VITATOPS trial, meta-analyses, and this succinct review. Take-Home Messages for Clinicians (i) High homocysteine levels are associated with increased risk of both stroke and coronary heart disease. (ii) Homocysteine can be lowered with folic acid (2.5 mg) and B-complex vitamin (50 mg B6 and 1 mg B12) supplements. (iii) The routine use of HLT for cardiovascular prevention is not supported by the current available evidence. (iv) Individuals with ischemic stroke and hyperhomocysteinemia may benefit from HLT for secondary prevention. (v) Although Vitamin B complex does not appear to have major side effects, caution must be exercise in patients with renal failure or decreased glomerular filtration rate. Acknowledgments I thank Dr J. David Spence for his comments and suggestions. Disclosures G.S. receives salary support from the Clinician Scientist Award from the Heart and Stroke Foundation of Ontario. G.S. s research has been funded by Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, Department of Research at St Michael s Hospital and Connaught Foundation (University of Toronto). References 1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325: Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in us physicians. JAMA. 1992;268: Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet. 2005;365: McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56: Kelly PJ, Furie KL. Management and prevention of stroke associated with elevated homocysteine. Curr Treat Options Cardiovasc Med. 2002;4: Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47: Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291: Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:
5 Saposnik Vitamin B in Stroke Prevention 5 9. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R. Effects of homocysteine-lowering with folic acid plus vitamin b12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303: Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354: Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, Guo W, Dawsey SM, Li B, Blot WJ. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol. 1996;143: Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298: Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300: Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299: VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the vitamins to prevent stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebocontrolled trial. Lancet Neurol. 2010;9: Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369: Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke. 2005;36: Spence JD. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial. Clin Chem Lab Med. 2007;45: Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteinelowering therapy and stroke risk, severity, and disability. Additional findings from the HOPE 2 trial. Stroke. 2009;40: Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc. 2002;50: Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6: House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010;303: Spence JD, House AA, Eliasziw M. B vitamin therapy for diabetic nephropathy [Reply]. JAMA. 2010;304: Koyama K, Ito A, Yamamoto J, Nishio T, Kajikuri J, Dohi Y, Ohte N, Sano A, Nakamura H, Kumagai H, Itoh T. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis. 2010;55: Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteinelowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41: Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bonaa KH, Spence JD, Nygard O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, Collins R. Effects of lowering homocysteine levels with b vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving individuals. Arch Intern Med. 2010;170: Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296: Mei W, Rong Y, Jinming L, Yongjun L, Hui Z. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2010;64: Miller ER III, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol. 2010;106: Wang H, Fan D, Zhang H, Fu Y, Zhang J, Shen Y. Serum level of homocysteine is correlated to carotid artery atherosclerosis in Chinese with ischemic stroke. Neurol Res. 2006;28: Saposnik G. Meta analysis suggests that folic acid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention. Evid Based Med. 2010;15: Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288: Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328: Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297: Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142: Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA. Guidelines for the primary prevention of stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke Dec 6 [Epub ahead of print]. 38. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42: KEY WORDS: folic acid homocysteinemia meta-analysis prevention stroke management Vitamin B complex
Folate and prevention of neural tube defects: Tracking red blood cell concentrations will help guide policy decisions about fortification
Folate and prevention of neural tube defects: Tracking red blood cell concentrations will help guide policy decisions about fortification Derrick Bennett, University of Oxford, UK 8 October, 2014 IXth
More informationReview Article The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis
Int J Clin Exp Med 2014;7(8):1923-1930 www.ijcem.com /ISSN:1940-5901/IJCEM0001191 Review Article The association between B vitamins supplementation and adverse cardiovascular events: a meta-analysis Wen-Feng
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationMcCully postulated in 1969 that homocysteine affected
Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials Yanping Li, PhD; Tianyi Huang, ScD; Yan Zheng, PhD; Tauland Muka, PhD; Jenna Troup, MPH;
More informationHomocysteine is a sulfur-containing amino
IN THE LITERATURE Approaching the End of the Homocysteine Hype? The following is a commentary on Jamison RL, Hartigan P, Kaufman JS, et al: Effect of homocysteine lowering on mortality and vascular disease
More informationAppendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa
Appendix 1 Characteristics of Trials Included in the Final Meta-Analysis (n = 50) [posted as supplied by author] Duration of Supplementa Participants tion, y (Average Age, y; (Follow-up Intervention vs.
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationFolic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis of Randomized Controlled Trials
Journal of Stroke 2018;20(1):99-109 https://doi.org/10.5853/jos.2017.01522 Original Article Folic Acid in Stroke Prevention in Countries without Mandatory Folic Acid Food Fortification: A Meta-Analysis
More informationSevere hyperhomocysteinemia, a feature of inborn errors
Efficacy of Homocysteine-Lowering Therapy With Folic Acid in Stroke Prevention A Meta-Analysis Meng Lee, MD; Keun-Sik Hong, MD, PhD; Shen-Chih Chang, PhD; Jeffrey L. Saver, MD Background and Purpose Although
More informationJust To Be on the Safe Side: Don t Take Vitamins
Just To Be on the Safe Side: Don t Take Vitamins No one loves me more than my mother; even though there were times during my childhood when I thought she was trying to poison me. Could the chemical aftertaste,
More informationNQF ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: The Joint Commission Only CMS Voluntary Only
Last Updated: Version 4.4a NQF ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Stroke (STK) Set Measure ID #: Measure Information Form Collected For: The Joint Commission Only CMS
More informationAlthough a number of prospective observational studies. Vascular Medicine
Vascular Medicine B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease Results of a Randomized Controlled Trial Judith Heinz, MSc; Siegfried Kropf, PhD; Ute
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2017 Related Policies: None Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
More informationORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease
ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:
More information1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
More informationA Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II
A Randomized Trial of a Multivitamin (MVM) in the Prevention of Cardiovascular Disease in Men: The Physicians Health Study (PHS) II Presenter Disclosure Information Howard D. Sesso, ScD, MPH Relevant Disclosures:
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationHomocysteine Testing Corporate Medical Policy
File name: Homocysteine Testing File code: UM.DIAG.02 Origination: 1/2011 Last Review 06/2017 Next Review: 06/2018 Effective Date: 11/01/2017 Homocysteine Testing Corporate Medical Policy Description Homocysteine
More informationHomocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease Policy Number: 2.04.23 Last Review: 07/2017 Origination: 07/2015 Next Review:
More informationMedical Coverage Policy Homocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease
Medical Coverage Policy Homocysteine Testing in the Screening and Diagnosis and Management of Cardiovascular Disease EFFECTIVE DATE:05 02 2017 POLICY LAST UPDATED:10 02 2018 OVERVIEW Homocysteine is an
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationFolic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta- Analysis
Article Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta- Analysis Xianhui Qin,* Yong Huo, Craig B. Langman, Fanfan Hou, Yundai Chen, Debora Matossian, Xiping
More informationIndependent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels
Independent Risk Factors of Cardiovascular Disease Achieving Healthy Homocysteine Levels AUTHORS: JON LEGERE, BRADLEY RALPH, DR. RON LEGERE 15344 N 83RD WAY, SCOTTSDALE, AZ 85260 TEL: 800.528.3144 EMAIL:
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationORIGINAL INVESTIGATION. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease
ORIGINAL INVESTIGATION An Update on in the Primary Prevention of Cardiovascular Disease Rachel S. Eidelman, MD; Patricia R. Hebert, PhD; Steven M. Weisman, PhD; Charles H. Hennekens, MD, DrPH Background:
More informationOBSERVATIONAL STUDIES
ORIGINAL CONTRIBUTION Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B 12 vs on Mortality and Major Morbidity in Myocardial Infarction Survivors A Randomized Trial Study of the Effectiveness
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationPage: 1 of 11. Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease
Last Review Status/Date: June 2015 Page: 1 of 11 Diagnosis and Management of Description Homocysteine is an amino acid found in the blood; levels are inversely correlated with folate levels. Homocysteine
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationLong-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationSaturated fat- how long can you go/how low should you go?
Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationDownloaded from:
Evans, JR; Lawrenson, JG (2013) Dietary interventions for AMD: what do we know and what do we not know? The British journal of ophthalmology. ISSN 0007-1161 DOI: https://doi.org/10.1136/bjophthalmol- 2013-303134
More informationIt is said that we are what we eat. It is advertised that
Topical Reviews Vitamin Supplementation and Stroke Prevention Graeme J. Hankey, MD, FRCP, FRCP Edin, FRACP It is said that we are what we eat. It is advertised that vitamin supplements, of one kind or
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationVitamin B 12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products
Research Recherche Vitamin B 12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products Julie Robertson, Francesco Iemolo, Sally P. Stabler, Robert H.
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAspirin prevents stroke but not MI in women; Vitamin E has no effect on CV disease or cancer
MEDICAL GRAND ROUNDS CME CREDIT JULIE E. BURING, ScD* Professor of Medicine, Harvard Medical School; Division of Preventive Medicine, Brigham and Women s Hospital, Boston; principal investigator, Women
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationScope of the talk. Riboflavin, other dairy B vitamins and cardiovascular health. Epidemiology of milk consumption and CVD
Riboflavin, other dairy B vitamins and cardiovascular health Professor Hilary J Powers University of Sheffield United Kingdom Scope of the talk Importance of dairy products to B vitamin intakes Epidemiological
More informationScreening for Cardiovascular Risk (2/6/09)
Screening for Cardiovascular Risk (2/6/09) Andrew Nicolaides MS, FRCS, FRCSE, PhD (Hon) Emeritus Professor of Vascular Surgery, Imperial College, London, UK Chairman, Cardiovascular Disease Educational
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationREVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationIn a recent meta-analysis of randomized clinical trials, Miller
Brief Communication: The Prevalence of High Intake of Vitamin E from the Use of Supplements among U.S. Adults Earl S. Ford, MD, MPH; Umed A. Ajani, MBBS, MPH; and Ali H. Mokdad, PhD Article Background:
More informationThe secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy,
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. LEASURE, MD Results of the Management of Atherothrombosis With Clopidogrel in High-Risk atients Trial Implications for the Neurologist Marc Fisher, MD The secondary
More informationStroke is a major source of mortality and morbidity in the
AHA/ASA Guideline Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationChapter 8. M den Heijer, HPJ Willems, HJ Blom, WBJ Gerrits, M Cattaneo, S Eichinger, FR Rosendaal, GMJ Bos. Blood 2006 Sep 7 [Epub ahead of print]
Chapter 8 Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomized, placebo-controlled, double blind trial M den Heijer, HPJ Willems,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThis review is contributed by Professor Helene McNulty RD and Dr Mary Ward RD from the University of Ulster, Northern Ireland.
1.1.1 Folate This review is contributed by Professor Helene McNulty RD and Dr Mary Ward RD from the University of Ulster, Northern Ireland. 1.1.1.1 Summary In recent years there has been much interest
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationAlthough the association between blood pressure and
Two-Year Changes in Blood Pressure and Subsequent Risk of Cardiovascular Disease in Men Howard D. Sesso, ScD, MPH; Meir J. Stampfer, MD, DrPH; Bernard Rosner, PhD; J. Michael Gaziano, MD, MPH; Charles
More informationTitle: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.
Manuscript type: Invited Commentary: Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study. Authors: David C Wheeler 1 and Bertram
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationFolate is a B vitamin that is essential for the biosynthesis
Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack Results of a Randomized Placebo-Controlled Trial Graeme J. Hankey, MD, FRACP; John W. Eikelboom,
More informationGo low or no? Managing blood pressure in primary care. Hypertension is rarely an isolated risk factor
Cardiovascular system DEBATE Go low or no? Managing blood pressure in primary care There is much debate as to whether intensive blood pressure management, i.e. aiming for a systolic blood pressure less
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationHOMOCYSTEINE LEVELS HAVE
ORIGINAL CONTRIBUTION Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular Disease A Randomized Trial Christine M. Albert,
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationCARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE
CARING FOR A LOVED ONE AFTER A HEART ATTACK OR STROKE AFTER YOUR LOVED ONE HAS HAD A HEART ATTACK OR STROKE Heart attack and stroke affects the whole family. If your loved one has had a heart attack or
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationInterventions for lowering plasma homocysteine levels in dialysis patients (Review)
Charles Darwin University Nigwekar, Sagar; Kang, Amy; Zoungas, Sophia; Cass, Alan; Gallagher, Martin; Kulshrestha, Satyarth; Navaneethan, Sankar; Perkovic, Vlado; Strippoli, Giovanni; Jardine, Meg Published
More informationPapers in Press. Published March 1, 2007 as doi: /clinchem Nonstandard abbreviations: CVD, cardiovascular disease; MTHFR,
Papers in Press. Published March 1, 2007 as doi:10.1373/clinchem.2006.083881 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.083881 Clinical Chemistry 53:5 000 000 (2007)
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION Edoxaban (Lixiana SERVIER Canada Inc.) Indication: Prevention of Stroke and Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationNutrient supplements and cardiovascular disease: a heartbreaking story
1 of 8 03/4/2011 7:17 PM J Lipid Res. 2009 April; 50(Supplement): S429 S433. doi: 10.1194/jlr.R800027-JLR200. PMCID: PMC2674749 Copyright notice Nutrient supplements and cardiovascular disease: a heartbreaking
More informationAtherosclerotic cardiovascular disease (CVD) involving. Vitamin Supplementation and Cardiovascular Disease CLINICAL REVIEW. William T.
Vitamin Supplementation and Cardiovascular Disease William T. Donahoo, MD Abstract Objective: To review the evidence of the effectiveness of antioxidant vitamins for the prevention and treatment of cardiovascular
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationAbundant evidence has accumulated supporting the association
Folate, Vitamin B 6, and B 12 Intakes in Relation to Risk of Stroke Among Men Ka He, MD; Anwar Merchant, DMD; Eric B. Rimm, ScD; Bernard A. Rosner, PhD; Meir J. Stampfer, MD; Walter C. Willett, MD; Alberto
More information